Your browser doesn't support javascript.
loading
Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea.
Choi, Young-Sook; Ryu, Sukhyun; Kim, Ryu Kyung; Chiara, Achangwa; Baek, Soojin; Nam, Hojin; Park, Eunkyung; Kim, Eun Kyoung; Choe, Young June; Kwon, Donghyok; Choi, Won Suk.
Affiliation
  • Choi YS; Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.
  • Ryu S; Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kim RK; Korea Insurance Development Institute, Seoul, Korea.
  • Chiara A; Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Baek S; Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.
  • Nam H; Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.
  • Park E; Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.
  • Kim EK; Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.
  • Choe YJ; Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Kwon D; Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea. vethyok@korea.kr.
  • Choi WS; Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea. cmcws@hanmail.net.
J Korean Med Sci ; 39(37): e258, 2024 Sep 30.
Article in En | MEDLINE | ID: mdl-39355951
ABSTRACT

BACKGROUND:

This retrospective observational matched cohort study assessed the differences in critical infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the omicron-predominant period of the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the vaccine effectiveness of bivalent mRNA vaccine compared to unvaccinated individuals.

METHODS:

We collected COVID-19 case data from the Korean COVID-19 vaccine effectiveness cohort. We calculated the probability of critical COVID-19 cases by comparing the vaccinated and unvaccinated groups.

RESULTS:

The risk of being critically infected due to SAR-CoV-2 infection was 5.96 times higher (95% confidence interval, 5.63-6.38) among older individuals who were unvaccinated compared to those who received the bivalent COVID-19 vaccine.

CONCLUSION:

Our findings indicate that the bivalent vaccine reduces the disease burden of the SARS-CoV-2 omicron variant, particularly among the older population. Further studies are warranted to determine the effectiveness of booster doses of vaccines for SARS-CoV-2 infection.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: J Korean Med Sci Journal subject: MEDICINA Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: J Korean Med Sci Journal subject: MEDICINA Year: 2024 Document type: Article Country of publication: